Legend Biotech (LEGN) Gains from Investment Securities (2020 - 2025)

Legend Biotech (LEGN) has 6 years of Gains from Investment Securities data on file, last reported at -$53000.0 in Q2 2025.

• Quarterly Gains from Investment Securities fell 100.05% year-over-year to -$53000.0 in Q2 2025, while the trailing twelve-month figure through Sep 2025 was -$149.8 million (down 163.6% YoY) and the FY2023 annual result came in at $85.8 million, up 14560.37% from the prior year.
• Gains from Investment Securities declined to -$53000.0 in Q2 2025, from $53000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $108.2 million in Q2 2024 to a low of -$149.8 million in Q4 2024.
• A 5-year average of $21.0 million and a median of $64500.0 in 2021 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2021 — Gains from Investment Securities plunged 163900.0% — and 2024, when it surged 144314.67%.
• Tracing LEGN's Gains from Investment Securities over 5 years: stood at $50.1 million in 2021, then soared by 99.66% to $100.0 million in 2022, then retreated by 14.24% to $85.8 million in 2023, then sank by 274.69% to -$149.8 million in 2024, then soared by 99.96% to -$53000.0 in 2025.
• The last three Gains from Investment Securities figures came in at -$53000.0 (Q2 2025), $53000.0 (Q1 2025), and -$149.8 million (Q4 2024), per Business Quant data.